August 2021
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
When it happened…
Tuesday, 20 July 2021
What delegates came to discuss…
This conference will consider priorities for the life sciences sector, options for utilising funding, and what is needed for driving competitiveness.
It will be an opportunity to discuss the recent publication of the Life Sciences Vision, which sets out the Government and life sciences sector’s ambitions for the next 10 years, and aims to encapsulate the sector’s successful developments during the pandemic to take them forward and apply them to other major health challenges, with £200m of funding announced through a Life Sciences Investment Programme.
Areas of focus include:
- how to improve competitiveness for the sector following Brexit and the pandemic
- opportunities for expansion going forward, with the introduction of the ARIA
- options and priorities for supporting growth and innovation in the sector, as well as tackling barriers
- what has been learned from the process of life sciences research during the pandemic
We are pleased to be able to include keynote sessions with Dr Nicole Mather, Non-Executive Director, Health Research Authority; and Executive Partner and Life Sciences Lead, IBM; and Dr Richard Torbett, Chief Executive, The Association of the British Pharmaceutical Industry - as well as contributions from NICE; The Association for Clinical Biochemistry and Laboratory Medicine (ACB); BIVDA; the British Science Association; Deepbridge Capital; LifeArc; iMATCH (Innovate Manchester Advanced Therapy Centre Hub); MHRA; and the Northern Health Science Alliance.
The agenda will bring out latest thinking on:
- policy - progress in the Life Sciences Industrial Strategy, and next steps for the sector following proposals set out in the Queen’s Speech
- investment and infrastructure - priorities for development to boost UK competitiveness
- international collaboration - opportunities following the UK leaving the EU
- wider impact of health research - supporting growth and innovation in the sector to meet ambitions across health and social care, including improving access
Who attended…
Officials from BEIS; the Cabinet Office; the Department for International Trade; the Department of Health and Social Care; the Government Office for Science; the Intellectual Property Office; the Medicines and Healthcare products Regulatory Agency; the Office for Life Sciences; The Scottish Government and the Welsh Government.
Representatives from AstraZeneca; Bird & Bird; Boehringer Ingelheim; Clarion Solicitors; Creative Places; FarmaTrust; Great Western Hospitals NHS Foundation Trust; Illumina Cambridge; Imperial College London; M&F Health; McKesson; Medicines Discovery Catapult; National Institute for Health Research; OpenCell; Organon; PerkinElmer; Pfizer; Phil Collis; Rare Autoinflammatory Conditions Community; Res Consortium; Roche Diagnostics; Teesside University; University of Kent; Vertex Pharmaceuticals and Yorkshire & Humber Academic Health Science Network.
Press passes have been reserved by representatives from APM Health Europe and POLITICO.
